Get the Stockscreener App
28.68
2.87%
0.80
Pharvaris Nv stock is traded at $28.68, with a volume of 134.77K.
It is up +2.87% in the last 24 hours and up +12.82% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
See More
Previous Close:
$27.88
Open:
$27.76
24h Volume:
134.77K
Relative Volume:
0.81
Market Cap:
$1.88B
Revenue:
-
Net Income/Loss:
$-198.12M
P/E Ratio:
-8.5127
EPS:
-3.3691
Net Cash Flow:
$-159.74M
1W Performance:
+3.02%
1M Performance:
+12.82%
6M Performance:
+36.83%
1Y Performance:
+127.26%
1-Day Range:
$27.66
$28.78
1-Week Range:
$26.00
$28.78
52-Week Range:
$12.94
$29.85
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
28.68 | 1.74B | 0 | -198.12M | -159.74M | -3.3691 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Pharvaris (PHVS) officer has shares withheld to cover RSU tax obligations - Stock Titan
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. - The Motley Fool
Pharvaris' Chief Executive Officer Sold More Than 23,000 Shares. What Does This Indicate for Shareholders? - Bitget
How (PHVS) Movements Inform Risk Allocation Models - Stock Traders Daily
PHVS Options Volatility — NASDAQ:PHVS - TradingView — Track All Markets
PHVS Options Chain — NASDAQ:PHVS - TradingView — Track All Markets
Pharvaris Insider Sold Shares Worth $647,281, According to a Recent SEC Filing - marketscreener.com
Pharvaris (PHVS) CEO sells 23,333 shares in Rule 10b5-1 trades - Stock Titan
Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) officer covers RSU taxes with 1,167 withheld shares - Stock Titan
Assessing Pharvaris (PHVS) Valuation After 2025 Earnings Loss And Deucrictibant Milestone Updates - Sahm
HC Wainwright Forecasts Pharvaris FY2030 Earnings - Defense World
HC Wainwright Weighs in on Pharvaris FY2030 Earnings - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Pharvaris (NASDAQ:PHVS) Price Target Lowered to $51.00 at Royal Bank Of Canada - Defense World
Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris’ (PHVS) Investment Narrative? - Yahoo Finance
Pharvaris moves closer to new preventive treatment for rare swelling disorder - MSN
Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says - marketscreener.com
Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder - Benzinga
Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
RBC Trims Price Target on Pharvaris to $51 From $52, Keeps Outperform, Speculative Risk - marketscreener.com
Published on: 2026-04-05 13:07:26 - baoquankhu1.vn
Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)? - simplywall.st
Pharvaris (PHVS) accounting officer has 1,164 shares withheld for RSU tax obligations - Stock Titan
Pharvaris (PHVS) CTO-level executive corrects Form 3/A to 49,216 shares - Stock Titan
Pharvaris NV expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Pharvaris N.V.Ordinary Shares (NQ: PHVS - The Chronicle-Journal
Pharvaris N.V. (9EN.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pharvaris Q4 and Full Year 2025 Earnings: Net Loss Reaches €176M as Clinical Pipeline Advances - Bayelsa Watch
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones - ChartMill
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data - TipRanks
Pharvaris Q4 Loss Widens; Shares Down Pre-Bell - marketscreener.com
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - bitget.com
Pharvaris Announces Completion of Enrollment in CHAPTER-3 Study of Deucrictibant XR for HAE Prophylaxis, with Topline Data Expected in 3Q2026 - Quiver Quantitative
Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share - marketscreener.com
PHVS: Phase 3 HAE study enrollment completed; NDA submission and strong liquidity position maintained - TradingView — Track All Markets
Pharvaris (NASDAQ: PHVS) outlines HAE pipeline, capital needs and key risks - Stock Titan
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pharvaris (PHVS) deepens 2025 loss while pivotal HAE trials hit key milestones - Stock Titan
Pharvaris completes pivotal HAE study, data due in Q3 2026 - Stock Titan
Pharvaris (NASDAQ:PHVS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Does Pharvaris (PHVS) Have a Chance to Surge 59.93% According to Wall Street Analyst Predictions? - Bitget
Pharvaris NV (PHVS) price target increased by 20.90% to 45.73 - MSN
Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect? - sharewise.com
Trading Systems Reacting to (PHVS) Volatility - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World
Tudor Investment Corp ET AL Invests $1.94 Million in Pharvaris N.V. $PHVS - MarketBeat
Pharvaris N.V. (PHVS) Presents at 2026 Global Angioedema Leadership ConferenceSlideshow - Seeking Alpha
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):